Iopamidol
From Wikipedia, the free encyclopedia
|
Iopamidol
|
|
| Systematic (IUPAC) name | |
| N,N'-Bis(1,3-dihydroxypropan-2-yl)-5-[ [(2S)-2-hydroxypropanoyl]amino]-2,4,6
-triiodobenzene-1,3-dicarboxamide |
|
| Identifiers | |
| CAS number | ? |
| ATC code | V08 |
| PubChem | |
| Chemical data | |
| Formula | C17H22I3N3O8 |
| Mol. mass | 777.08 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | Intravascular |
Iopamidol (INN, tradenames Iopamiro, Isovue, and Iopamiron) is a nonionic, low-osmolar iodinated contrast agent, developed by Bracco.
It is available in various concentrations, from 200 to 370 mgI/mL.
[edit] Clinical uses
Iopamidol is primarily used in the following:[1]
- Angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography)
- Adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging
[edit] References
- ^ Bracco Diagnostic Inc. (April 2004). Iopamidol (Isovue) prescribing information (revised April 2004). DailyMed. U.S. National Library of Medicine. Retrieved on 2008-03-28.

